AstraZeneca halted a Phase 3 lung cancer study of volrustomig after an interim data review suggested survival goals were likely to be missed. The discontinuation follows a broader pattern of late-stage setbacks for the company and underscores the difficulty of advancing next-generation oncology combinations through pivotal readouts. The trial decision reflects an Independent Data Monitoring Committee’s interim assessment and narrows AstraZeneca’s pathway for expanding its lung cancer pipeline. Investors will now focus on what alternatives—other late-stage assets and biomarker strategies—can offset the opportunity lost with volrustomig. While the underlying data details were not fully described in the report, the company’s move to stop the Phase 3 program signals that the volrustomig regimen did not show sufficient confidence versus an established comparator strategy for the survival objectives set for the study.